JPH09508129A - α▲下2A▼アドレナリン受容体作動剤としての芳香族2−アミノ−イミダゾール誘導体 - Google Patents
α▲下2A▼アドレナリン受容体作動剤としての芳香族2−アミノ−イミダゾール誘導体Info
- Publication number
- JPH09508129A JPH09508129A JP7519767A JP51976795A JPH09508129A JP H09508129 A JPH09508129 A JP H09508129A JP 7519767 A JP7519767 A JP 7519767A JP 51976795 A JP51976795 A JP 51976795A JP H09508129 A JPH09508129 A JP H09508129A
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- methyl
- ring
- group selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式: [式中、R1は炭素数1〜4のアルキルもしくはアルケニル、シクロプロピル、 Cl、Br、I、−OR4、−SR4、−NR4R4または−Si(R4)3(R4は炭素数 1〜4のアルキルもしくはアルケニル、または水素)であり、R2およびR3は、 R1および水素から成る群から選択する基であるか;またはR1およびR2は共同 で、フェニル部分と縮合する環を形成し、−(CH2)4−、−NH(CH2)2NH− 、−O(CH2)2O−、−NH(CH2)2O−、−S(CH2)2S−、−NH(CH2) S−および−O(CH2)2S−から成る群から選択する基を構成し、R3はR1およ び水素から成る群から選択する基であるか;またはR2およびR3は共同で、フェ ニル部分と縮合する環を形成し、−(CH2)4−、−NH(CH2)2NH−、−O( CH2)2O−、−NH(CH2)2O−、−S(CH2)2S−、−NH(CH2)S−、− O(CH2)2S−、−CH=CH−CH=CH−、−N=CH−CH=N−および −N=CH−N=CH−から成る群から選択する基を構成し、R1がクロロの場 合、R2およびR3はいずれも水素である。] で示される化合物または薬学的に許容し得るその塩。 2.フェニル環は単環であり、R1、R2およびR3の各置換基のハメットσmet a値は0.4またはそれ以下であり、R2およびR3は水素であり得る請求項1記載 の化合物。 3.置換基R1のハメットσmetaは、0.15またはそれ以下である請求項2記 載の化合物。 4.R1は、メチル、エチル、n−プロピル、イソプロピル、ヒドロキシ、メト キシ、エトキシ、チオール、メタンチオール、エタンチオール、アミノ、N−メ チルアミノ、N,N−ジメチルアミノ、N−エチルアミノおよびN,N−ジエチル アミノから成る群から選択する基である請求項1記載の化合物。 5.R2およびR3が共同で、フェニル環に縮合した環を形成し、R1のハメッ トσmeta値は0.4またはそれ以下である請求項1記載の化合物。 6.R1のハメットσmeta値が、0.15またはそれ以下である請求項5記載の 化合物。 7.R1およびR2が共同で、−CH2−CH2−CH2−CH2−を構成する請求 項1記載の化合物。 8.R2およびR3が共同で、−NH−CH2−CH2−O−、−O−CH2−C H2−O−、−N=CH−CH=N−および−NH−CH2−CH2−NH−から 成る群から選択する基を構成し、R1のσmeta値は0.15またはそれ以下である 請求項1記載の化合物。 9.1−メトキシ−3−メチル−4−(2−イミダゾリル)アミノベンゼンであ る請求項1記載の化合物。 10.5−メチル−6−N−(2−イミダゾリル)アミノ−1,4−ベンゾジオ キサン;5−メチル−6−N−(2−イミダゾリル)アミノ−2,3−ジヒドロ− 1,4−ベンゾオキサジン;5−メチル−6−N−(2−イミダゾリル)アミノ− キノキサリン;および5−メチル−6−N−(2−イミダゾリル)アミノ−2,3 −ジヒドロ−キノキサリンから成る群から選択する請求項1記載の化合物。 11.α2Aアドレナリン受容体の選択的刺激を要する哺乳動物において該刺激 を行って処置効果を達成する方法であって、式: [式中、R1は炭素数1〜4のアルキルもしくはアルケニル、シクロプロピル、C l、Br、I、−OR4、−SR4、−NR4R4または−Si(R4)3(R4は炭素数1 〜4のアルキルもしくはアルケニル、または水素)であり、R2およびR3は、R1 および水素から成る群から選択する基であるか;またはR1およびR2は共同で、 フェニル部分と縮合する環を形成し、−(CH2)4−、−NH(CH2)2NH−、− O(CH2)2O−、−NH(CH2)2O−、−S(CH2)2S−、−NH(CH2)S− および−O(CH2)2S−から成る群から選択する基を構成し、R3はR1および水 素から成る群から選択する基であるか;またはR2およびR3は共同で、フェニル 部分と縮合する環を形成し、−(CH2)4−、−NH(CH2)2NH−、−O(CH2 )2O−、−NH(CH2)2O−、−S(CH2)2S−、−NH(CH2)S−、−O(C H2)2S−、−CH=CH−CH=CH−、−N=CH−CH=N−および−N =CH−N=CH−から成る群から選択する基を構成し、R1がクロロの場合、 R2およびR3はいずれも水素である。] で示される化合物もしくはその混合物または薬学的に許容し得るその塩を、処置 有効量で哺乳動物に投与することを含んで成る方法。 12.フェニル環は単環であり、R1、R2およびR3の各置換基のハメットσm eta値は0.15またはそれ以下であり、R2またはR3は水素であり得る請求項1 1記載の方法。 13.R1は、メチル、エチル、n−プロピル、イソプロピル、ヒドロキシ、メ トキシ、エトキシ、チオール、メタンチオール、エタンチオール、アミノ、N− メチルアミノ、N,N−ジメチルアミノ、N−エチルアミノおよびN,N−ジエチ ルアミノから成る群から選択する基である請求項11記載の方法。 14.処置効果は、少なくとも一方の眼における眼圧の降下または維持;末梢 痛の処置;麻酔剤の効果の増強;高血圧の処置;高血糖の処置;および鎮静から 成る群から選択する請求項11記載の方法。 15.R2およびR3が共同で、フェニル環に縮合した環を形成し、R1のハメ ットσmeta値は0.15またはそれ以下である請求項11記載の方法。 16.R1およびR2が共同で、−CH2−CH2−CH2−CH2−を構成する請 求項11記載の方法。 17.R2およびR3が共同で、−NH−CH2−CH2−O−、−O−CH2− CH2−O−、−N=CH−CH=N−および−NH−CH2−CH2−NH−か ら成る群から選択する基を構成し、R1のσmeta値は0.15またはそれ以下であ る請求項11記載の方法。 18.式(I)で示される化合物は、1−メトキシ−3−メチル−4−(2− イミダゾリル)アミノベンゼンである請求項11記載の方法。 19.式(I)で示される化合物は、5−メチル−6−N−(2−イミダゾリ ル)アミノ−1,4−ベンゾジオキサン;5−メチル−6−N−(2−イミダゾリ ル)アミノ−2,3−ジヒドロ−1,4−ベンゾオキサジン;5−メチル−6−N −(2−イミダゾリル)アミノ−キノキサリン;および5−メチル−6−N−(2 −イミダゾリル)アミノ−2,3−ジヒドロ−キノキサリンから成る群から選択す る請求項11記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18565394A | 1994-01-24 | 1994-01-24 | |
US18640694A | 1994-01-24 | 1994-01-24 | |
US08/185,653 | 1994-01-24 | ||
US08/186,406 | 1994-01-24 | ||
PCT/US1995/001150 WO1995019968A1 (en) | 1994-01-24 | 1995-01-24 | Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09508129A true JPH09508129A (ja) | 1997-08-19 |
JP3805360B2 JP3805360B2 (ja) | 2006-08-02 |
Family
ID=26881341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51976795A Expired - Fee Related JP3805360B2 (ja) | 1994-01-24 | 1995-01-24 | α▲下2A▼アドレナリン受容体作動剤としての芳香族2−アミノ−イミダゾール誘導体 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0741709B1 (ja) |
JP (1) | JP3805360B2 (ja) |
CA (1) | CA2181909C (ja) |
DE (1) | DE69521883T2 (ja) |
ES (1) | ES2160700T3 (ja) |
WO (1) | WO1995019968A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19514579A1 (de) | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
JPH11505224A (ja) * | 1995-05-12 | 1999-05-18 | アラーガン | 心臓血管系副作用を伴わないα▲下2▼アドレナリン作動剤として有用なアリール−イミダゾリンおよびアリール−イミダゾール |
CN1155383C (zh) | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途 |
US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
SK74999A3 (en) * | 1996-11-25 | 2000-02-14 | Procter & Gamble | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists |
US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6602897B2 (en) | 2000-10-14 | 2003-08-05 | Boehringer Ingelheim Pharma Kg | m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
DE10304374A1 (de) | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
CN101821254B (zh) * | 2007-08-15 | 2013-10-09 | 阿勒根公司 | 肾上腺素能化合物 |
IE20070935A1 (en) * | 2007-12-21 | 2009-06-24 | Trinity College Dublin | Guanidine based compounds and their use in the treatment of mental and neurological disorders. |
WO2022236253A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459763A (en) * | 1966-01-25 | 1969-08-05 | Geigy Chem Corp | Certain amino imidazole derivatives |
US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
-
1995
- 1995-01-24 JP JP51976795A patent/JP3805360B2/ja not_active Expired - Fee Related
- 1995-01-24 WO PCT/US1995/001150 patent/WO1995019968A1/en active IP Right Grant
- 1995-01-24 DE DE69521883T patent/DE69521883T2/de not_active Expired - Lifetime
- 1995-01-24 ES ES95910135T patent/ES2160700T3/es not_active Expired - Lifetime
- 1995-01-24 EP EP95910135A patent/EP0741709B1/en not_active Expired - Lifetime
- 1995-01-24 CA CA002181909A patent/CA2181909C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0741709A1 (en) | 1996-11-13 |
JP3805360B2 (ja) | 2006-08-02 |
EP0741709B1 (en) | 2001-07-25 |
WO1995019968A1 (en) | 1995-07-27 |
DE69521883D1 (de) | 2001-08-30 |
ES2160700T3 (es) | 2001-11-16 |
CA2181909C (en) | 2008-10-07 |
AU690645B2 (en) | 1998-04-30 |
DE69521883T2 (de) | 2002-04-04 |
CA2181909A1 (en) | 1995-07-27 |
AU1835195A (en) | 1995-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09508129A (ja) | α▲下2A▼アドレナリン受容体作動剤としての芳香族2−アミノ−イミダゾール誘導体 | |
JP2798095B2 (ja) | 特定アミノメチルフェニルイミダゾール誘導体、新種のドーパミン受容体サブタイプの特定リガンド | |
US6583166B1 (en) | Triazole compounds with dopamine-D3-receptor affinity | |
CN102325755B (zh) | 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物 | |
US10172863B2 (en) | Purine derivatives useful as HSP90 inhibitors | |
TWI473803B (zh) | 作為阿伐7正向異位調節劑之嗎福啉基噻唑 | |
JP2504879B2 (ja) | アゾ―ル誘導体 | |
NZ250944A (en) | Substituted benzazepines and analogs thereof; use as medicaments | |
JP2010018634A (ja) | [1,2,4]−トリアゾール二環式アデノシンA2aレセプタアンタゴニスト | |
KR20180004193A (ko) | Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드 | |
JPH0673024A (ja) | キナゾリノン類及びピリドピリミジノン類 | |
JP3971298B2 (ja) | テトラゾール誘導体 | |
JP3683911B2 (ja) | α−拮抗活性を有するキナゾリニル−アミノ誘導体 | |
CN103717593B (zh) | 调节激酶的组合物和方法 | |
JP2000511534A (ja) | ベンゾオキサジノンドーパミンd4受容体アンタゴニスト | |
SE466309B (sv) | 1-pyrimidinyloxi-3-hetarylalkylamino-2-propanoler, farmaceutisk komposition och framstaellning daerav | |
JP2002527513A (ja) | ヒスタミン−h3アゴニストまたはアンタゴニストとしてのn−(イミダゾリルアルキル)置換環式アミン | |
JP2000505428A (ja) | ヒスタミンh▲下3▼レセプターリガンド | |
JPH06211845A (ja) | ベンゾフラン誘導体 | |
JPH0656783A (ja) | ビフエニルメチル置換ピリドン類 | |
EA027882B1 (ru) | Этинильные производные в качестве антагонистов метаботропного глутаматного рецептора | |
NZ198321A (en) | 2-(1,4-benzodioxan-2-ylalkyl)-imidazoles | |
JPH0641464B2 (ja) | ジヒドロピリジン類 | |
JP5974179B2 (ja) | アリールエチニル誘導体 | |
JP2002529458A (ja) | PPAR−γリガンド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041130 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060123 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060510 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100519 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110519 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120519 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130519 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |